Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Simcere Zaiming Pharmaceutical / Equity Capital Markets

<ul>
<li>Simcere Zaiming, a biopharma spin-off from Simcere Pharmaceutical, is looking to raise at least USD 100 million via a Hong Kong listing. MS and CICC are the joint sponsors.</li>
<li>In this note, we look at the company’s commercial products and four clinical-stage products.</li>
<li>We also look at the company’s pre-IPO investors and management team.</li>
</ul>


Simcere Zaiming, a biopharma spin-off from Simcere Pharmaceutical, is looking to raise at least USD 100 million via a Hong Kong listing. MS and CICC are the joint sponsors.
In this note, we look at the company’s commercial products and four clinical-stage products.
We also look at the company’s pre-IPO investors and management team.


Simcere Zaiming (先声再明) Pre-IPO: A Credible Oncology-Focused Biopharma Spin-Off